| 产品描述: | Mal-Val-Ala-PAB-N(SO2Me)-Exatecan (Compound LE14) is a conjugate of an ADC toxin Exatecan and a linker Mal-Val-Ala-PAB-N(SO2Me). Mal-Val-Ala-PAB-N(SO2Me)-Exatecan can be used for synthesis of ADC FZ-AD005. FZ-AD005 is a delta-like ligand 3 (DLL3, KD=58.3 pM) targeting ADC, that exhibits antitumor efficacy against SCLC cancer. |
| 体外研究: |
ADC 由一种抗体组成,ADC 细胞毒素通过 ADC 接头连接到该抗体上。 |
| 参考文献: |
1. Guo Q, et al., FZ-AD005, A Novel DLL3-Targeted Antibody-drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models. Mol Cancer Ther. 2024 Jun 28.
|
| 保存条件: |
-20°C |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
0.876 ml |
4.381 ml |
8.763 ml |
| 5 mM |
0.175 ml |
0.876 ml |
1.753 ml |
| 10 mM |
0.088 ml |
0.438 ml |
0.876 ml |
| 50 mM |
0.018 ml |
0.088 ml |
0.175 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |